Nordson separation agreement for departing segment leader Lovass: $832,759 cash, continued vesting

NORDSON CORP

Stephen Lovass ceased as Medical and Fluid Solutions segment leader; assists transition until June 1, 2025, then separates.
Receives $832,759 cash (severance plus COBRA) and pro-rata FY2025 annual incentive under separation agreement.
Stock options granted on/before Dec 1, 2022 continue vesting; exercisable until June 1, 2030 or original expiry.
Restricted shares/units from same period vest pro-rata; PSUs from Dec 1, 2022 vest pro-rata based on actual performance.
One-year non-compete, non-solicitation; indefinite confidentiality, non-disparagement; outplacement up to $10k, financial planning up to $5k.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Stephen Lovass

segment leader for the Medical and Fluid Solutions Segment

NDSN · NORDSON CORP

Effective: 2025-04-28
Filed: June 11, 2025, 7:59 PM ET

the Original Form 8-K reported that, on April 28, 2025, Stephen Lovass ceased to serve as segment leader for the Medical and Fluid Solutions Segment of Nordson Corporation

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Lovass departed as segment leader for the Medical and Fluid Solutions Segment at NORDSON CORP.

Action: ceased to serve
Role: segment leader for the Medical and Fluid Solutions Segment

Exact text from the filing

the Original Form 8-K reported that, on April 28, 2025, Stephen Lovass ceased to serve as segment leader for the Medical and Fluid Solutions Segment of Nordson Corporation

View on SEC.gov

NORDSON CORP filing history →

Source: SEC EDGAR

accession 0000072331-25-000074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.